Sign in

EXOZ on Nasdaq

EXOZYMES INC.

EXOZYMES INC. is an American biological products company that raised $12,000 in 2024 (SEC Form D).1 It is headquartered in Monrovia, California.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with BioCardia, Inc., AIM ImmunoTech Inc. or Inmune Bio, Inc., or pick any stock.

  • TickerEXOZ on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersMonrovia, California1
  • Incorporated inNV2
  • Business address750 Royal Oaks Dr, Monrovia, Ca 910162
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Inc. has also received grants from two non-government sources. One of the grants was from the Gates Foundation for work on terpene synthesis.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-2563.5%Operating margin4
-2909.1%Net margin4
-$1.5MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Research and development93¢$527.5K
  • Income tax7¢$42.3K

Out of $70.1K in revenue.45 The company lost money this year.

Financial statements

Every line of the income statement as filed: the last 3 fiscal years, latest first.5

Period ending2025-12-312024-12-312023-12-31
Compensation$3.6M$2.5M
Professional fees$1.4M$1.2M
Information technology$96.0K$38.7K
General and administrative-other$836.1K$329.7K
Total general and administrative costs$6.0M$4.1M
Research and development costs$3.7M$1.9M
Total operating costs$9.7M$5.9M
Net operating loss-$9.7M-$5.9M
Interest income, net$363.8K$77.6K
Other income/(expense)$88.7K-$6.8K
Change in fair value of SAFE-$8
Loss before income taxes-$9.3M-$5.9M
Income tax benefit$105.2K-$42.3K
Net loss-$9.2M-$5.9M
Net loss per common share - basic-$1.09-$0.89
Net loss per common share - diluted-$1.09-$0.89
Weighted average of common shares outstanding - basic8.4M shares6.6M shares
Weighted average of common shares outstanding - diluted8.4M shares6.6M shares

Compare EXOZYMES INC. with another company

Corporate structure

EXOZYMES INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of EXOZYMES INC.

  • EXOZYMES INC. Monrovia, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What EXOZYMES INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$1.8M5 Dec 31, 2025$1.6M5 Dec 31, 2024+10.5%
Accumulated depreciation$1.0M5 Dec 31, 2025$728.7K5 Dec 31, 2024+39.5%
Property and equipment, net$764.4K5 Dec 31, 2025$882.4K5 Dec 31, 2024−13.4%
Finance-lease assets$108.7K5 Dec 31, 2025
Operating-lease assets (leased space)$1.1M5 Dec 31, 2025$1.3M5 Dec 31, 2024−20.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$3.0M5 Dec 31, 2025$9.7M5 Dec 31, 2024−68.7%

Properties, in its own words

Our headquarters and R&D facilities are currently located in Monrovia, California. We lease approximately 10,000 square feet of recently renovated space. Of the total space, a portion is reserved for R&D pilot activities and the balance of the space is split among the general and administrative office, R&D laboratory requirements, fermentation uses to develop and produce needed enzymes, and to house an analytical lab. The Company believes its existing facility is in good operating condition and suitable for its future operations as of the period end December 31, 2025.

Item 2 of the 10-K filed Mar 30, 2026.3

Leadership

Who has led EXOZYMES INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Michael Heltzen2024–now

Chair

  1. Mohammad Hayat2024

President

  1. Mohammad Hayat2024
2025
Board members and other officers (9)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorJames Lalonde named Nov 19, 202419

Former names

  • Invizyne Technologies IncFeb 9, 2024 to Jan 21, 20252

Timeline

  1. Oct 9, 20268-K Other events20
  2. Sep 18, 20268-K Other events21
  3. Jul 1, 20268-K Entered a material agreement22
  4. Jun 26, 20268-K Regulation FD disclosure23
  5. Jun 17, 20268-K Entered a material agreement; Regulation FD disclosure24
  6. Jun 8, 20268-K Entered a material agreement; Regulation FD disclosure25
  7. May 7, 20268-K Other events26
  8. Apr 10, 20268-K Other events27
  9. Mar 31, 20268-K Other events28
  10. Feb 5, 20268-K Other events29
  11. Dec 12, 20258-K Other events30
  12. Nov 13, 20258-K Other events31
  13. Nov 18, 2024New chief executive Michael Heltzen becomes CEO8

Calendar

Coming up

  1. Nov 12, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.27) a share, on Nov 13, 2025.32

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

120 filings to the SEC since October 2021: 2 annual reports, 6 quarterly reports, 22 major events, 32 insider forms, 4 large holders, 1 private raises, 53 other. The latest 20:

  1. Oct 9, 20268-K EDGAR
  2. Sep 28, 2026DEFA14A EDGAR
  3. Sep 28, 2026DEF 14A EDGAR
  4. Sep 18, 20268-K EDGAR
  5. Sep 17, 20264 EDGAR
  6. Sep 2, 20264 EDGAR
  7. Aug 25, 20264 EDGAR
  8. Aug 25, 20264 EDGAR
  9. Aug 13, 202610-Q EDGAR
  10. Jul 1, 20268-K EDGAR
  11. Jun 30, 2026424B5 EDGAR
  12. Jun 26, 20268-K EDGAR
  13. Jun 17, 20268-K EDGAR
  14. Jun 8, 20268-K EDGAR
  15. Jun 8, 2026424B5 EDGAR
  16. Jun 4, 2026424B5 EDGAR
  17. May 29, 2026424B5 EDGAR
  18. May 14, 202610-Q EDGAR
  19. May 7, 20268-K EDGAR
  20. Apr 10, 20268-K EDGAR

The 120 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

8 open-market trades by officers, directors and large owners since October 2021: 6 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 26, 2026Heltzen MichaelChief Executive OfficerBuy505$7.48$3.8KForm 4
Aug 25, 2026Heltzen MichaelChief Executive OfficerBuy350$7.51$2.6KForm 4
Apr 9, 2026Korman Tyler PazChief Scientific OfficerSale750$10.53$7.9KForm 4
Apr 8, 2026Korman Tyler PazChief Scientific OfficerSale750$10.04$7.5KForm 4
Jul 2, 2025Heltzen MichaelChief Executive OfficerBuy1,040$10.22$10.6KForm 4
Jan 17, 2025Heltzen MichaelChief Executive OfficerBuy1,767$10.78$19.0KForm 4
Jan 16, 2025Heltzen MichaelChief Executive OfficerBuy121$10.72$1.3KForm 4
Nov 15, 2024Heltzen MichaelChief Executive OfficerBuy1,984$11.10$22.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Michael HeltzenPresident and CEO$358.3K$1.1M37
2025Fouad NawazVice President, Finance$214.6K$351.7K37
2025Tyler KormanChief Scientific Officer$222.9K$314.8K37
2025Damien PerrimanChief Commercial Officer$237.8K$310.8K37
2025Paul OpgenorthVice President, Development$219.8K$310.6K37
2024Michael HeltzenPresident and CEO$231.2K$381.3K37
2024Tyler KormanChief Scientific Officer$191.2K$265.9K37
2024Paul OpgenorthVice President, Development$190.0K$261.8K37
2024Fouad NawazVice President, Finance$168.8K$213.1K37

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Nov 14, 2024Raised $11,718 in a private offering of securities Form D: 2 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Vanguard Capital Management LLC54,985$463.5K0.0%+32,795
Davidson Kahn Capital Management, LLC25,000$210.8K0.1%New
Geode Capital Management, LLC23,406$197.3K0.0%+1,515
BlackRock, Inc.9,610$81.0K0.0%+2,813
Vanguard Fiduciary Trust Co9,426$79.5K0.0%No change
Morgan Stanley1,250$10.5K0.0%No change
Tower Research Capital LLC (TRC)349$2.9K0.0%−968
UBS Group AG203$1.7K0.0%+179
Barclays PLC75$6320.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How EXOZYMES INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAREXOZYMES INC.1
  • CIK0002010788
  • Employer ID (EIN)83-45500573
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; a shell company3
  • Incorporated inNevada3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address750 Royal Oaks Dr, Monrovia, CA 910161
  • Phone(626) - 415 - 14881
  • Shares outstanding9,281,359 as of Aug 13, 20267
  • Public float$38.4M as of Jun 30, 20253
  • AuditorRBSM LLP, Las Vegas, Nevada PCAOB ID 587; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceFeb 9, 20241
  • Filings120 in all: 8-K (22), 4 (19), 3 (13), CORRESP (13), S-1/A (8), 10-Q (6), UPLOAD (6), 424B5 (5)1
    All 25 form types

    SC 13D (4), 424B3 (3), 10-K (2), 424B4 (2), DEF 14A (2), EFFECT (2), FWP (2), S-8 (2), 424B2 (1), 8-A12B (1), CERT (1), D (1), DEFA14A (1), DEFR14A (1), DRS (1), S-1 (1), S-3 (1)

  • Latest filingsAnnual report (10-K) Mar 30, 2026
    Quarterly report (10-Q) Aug 13, 2026
    Proxy statement (DEF 14A) Sep 28, 2026
    Latest 8-K (8-K) Oct 9, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $.000001EXOZNasdaq

From the cover page of the 10-K filed Mar 30, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks EXOZYMES INC. names in Item 1A of its 10-K filed Mar 30, 2026: 45 risks under these headings, as written.3

  • Business Risk Factors
  • eXoZymes has a limited operating history on which to evaluate its ability to achieve its operating objectives.
  • We cannot assure you that we will generate revenue or become profitable in the future.
  • We may need additional capital to support our growth over time. Additional capital may be difficult to obtain thus restricting our operations and resulting in additional dilution to our stockholders.
  • In the future, we may not be able to obtain government and private grants which have been an important source of funding our operations since inception.
  • We are unsure if and when eXoZymes will become profitable.
  • eXoZymes may not be successful in its efforts to use its proprietary biomanufacturing platform to build a pipeline of products.
  • The market, including clients and potential investors, may be skeptical of the viability and benefits of eXoZymes’s pipeline chemical products because they are relatively novel and are based on complex technology.
  • The synthetic biology market is a rapidly expanding and changing market, and if eXoZymes is unable to keep up to date with developments, its business may be adversely affected.
  • eXoZymes may face unique regulatory hurdles because its bio-synthesized compounds are novel.
  • Because its chemical and small molecule compounds are novel, eXoZymes may have to perform tests for safety, use, approval and claim validation.
  • eXoZymes is highly dependent on its ability to retain its current management and its scientific team and other staff to run the company, and be able to recruit and hire additional employees with specialized backgrounds as needed.
The other 34 risks
  • Our ability to retain our senior management and recruit additional senior management is important to the success of our business, and our failure to do so may adversely affect our reputation, business, results of operations and financial condition.
  • Laboratory conditions differ from commercial conditions, which could affect the effectiveness of our potential products. Failures to effectively move from laboratory to commercial scale would harm our business.
  • Our systems rely on the need for purified enzymes and co-factors for the conversions of input feedstock into final products. We will need to find competitively priced sources of, or ways of making these inputs for our process to be cost competitive and/or develop methods to use these resources efficiently.
  • We will be subject to fluctuations in pricing for the products we choose to develop and commercialize.
  • Our business depends upon our ability to make good decisions regarding the deployment of capital and, ultimately, the performance of our products which is uncertain.
  • Our success depends, in part, on the successful development of our science technologies and our products.
  • We are subject to risks relating to portfolio concentration.
  • We are subject to risks related to our NCT program and commercialization efforts.
  • We do not have any manufacturing and distribution capabilities or arrangements, and will need to create these as we move towards commercialization of our products.
  • Collaborations of various sorts, by our partner companies, such as with respect to research, testing, manufacturing and distribution, will be important to our business. The inability to enter into collaboration arrangements as needed, or if such collaborations are not successful, may adversely impact our business.
  • We expect to experience competition from other companies and research institutions.
  • Risks Related to Intellectual Property and Other Legal Matters
  • If we are unable to protect the intellectual property used in our technology platform and products, others may be able to copy our innovations which may impair our ability to compete effectively in our markets.
  • If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected.
  • If we fail to comply with our obligations in the agreements under which we license development or commercialization rights to products or technology from third-parties, we could lose license rights that are important to our business.
  • Our license fees to The Regents may exceed our income from product revenues based on the licensed patents.
  • If we or our licensors are unable to protect our/their intellectual property, then our financial condition, results of operations and the value of our technology and products could be adversely affected.
  • Litigation or third-party claims of intellectual property infringement or challenges to the validity of our patents would require us to use resources to protect our technology and may prevent or delay our development or commercialization of our product candidates.
  • Third-party claims of intellectual property infringement may prevent or delay our development and commercialization activities for other products.
  • We may become involved in future lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming and unsuccessful.
  • If trademarks and trade names are not adequately protected, then we may not be able to build name recognition in the markets of interest and our business may be adversely affected.
  • Risks Related to this Being a Public Company
  • We incur substantial costs as a result of operating as a public company, and our board of directors is required to devote substantial time to oversight of our compliance requirements and corporate governance practices.
  • We are a smaller reporting company within the meaning of the Securities Act, and while we take advantage of certain exemptions from disclosure requirements available to smaller reporting companies, this could make our securities less attractive to investors and may make it more difficult to compare our performance with other public companies.
  • If we fail to develop or maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent financial fraud. As a result, current and potential stockholders could lose confidence in our financial reporting.
  • We currently have a single facility that is our main office and laboratory. Any disruption in our ability to operate from this facility would delay our research and development efforts and does pose an operational risk.
  • Our Common Stock may experience rapid and substantial price volatility, and price decline, which may make it difficult for prospective investors to assess what we believe to be the value of our Common Stock.
  • Concentration of ownership among our existing executive officers, directors and significant stockholders may prevent new investors from influencing significant corporate decisions.
  • Our failure to meet the continued listing requirements of Nasdaq could result in a delisting of our Common Stock.
  • We are an “emerging growth company” under the JOBS Act and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our Common Stock less attractive to investors.
  • Our status as an “emerging growth company” under the JOBS Act may make it more difficult to raise capital as and when we need it.
  • We anticipate that any public market for our Common Stock will be volatile. This may affect the ability of our investors to sell their shares as well as the price at which they may be able to sell their shares.
  • Shares eligible for future sale may adversely affect the market for our Common Stock.
  • We may have an increased risk of securities class action litigation as a result of our being a public reporting company and trading in the public market.
  • We have not paid cash dividends in the past and have no immediate plans to pay cash dividends.
  • We have technology that might be interesting to bad actors, foreign actors or nation states that has very different legal frameworks and belief system than ours.

Legal proceedings

From time to time, we may be a party to certain legal proceedings in the ordinary course of business, including proceedings relating to the enforcement of our rights under contracts with our customers. While the outcome of these legal proceedings cannot be predicted with certainty, we do not expect that these proceedings will have a material effect upon our financial condition or results of operations.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
    SEC EDGAROther events
  21. 21
    SEC EDGAROther events
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
    SEC EDGAROther events
  27. 27
    SEC EDGAROther events
  28. 28
    SEC EDGAROther events
  29. 29
    SEC EDGAROther events
  30. 30
    SEC EDGAROther events
  31. 31
    SEC EDGAROther events
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37